Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid β-Amyloid 42 in Healthy Middle-Aged Men

Abstract

Increasing evidence suggests a relationship between poor sleep and the risk of developing Alzheimer disease. A previous study found an effect of sleep on β-amyloid (Aβ), which is a key protein in Alzheimer disease pathology. OBJECTIVE To determine the effect of 1 night of total sleep deprivation on cerebrospinal fluid Aβ42 protein levels in healthy middle-aged men. DESIGN, SETTING, AND PARTICIPANTS The Alzheimer, Wakefulness, and Amyloid Kinetics (AWAKE) study at the Radboud Alzheimer Center, a randomized clinical trial that took place between June 1, 2012, and October 1, 2012. Participants were cognitively normal middle-aged men (40-60 years of age) with normal sleep (n = 26) recruited from the local population. INTERVENTIONS Participants were randomized to 1 night with unrestricted sleep (n = 13) or 1 night of total sleep deprivation (24 hours of wakefulness) (n = 13). MAIN OUTCOMES AND MEASURES Sleep was monitored using continuous polysomnographic recording from 3 PM until 10 AM. Cerebrospinal fluid samples were collected using an intrathecal catheter at defined times to compare cerebral Aβ42 concentrations between evening and morning. RESULTS A night of unrestricted sleep led to a 6% decrease in Aβ42 levels of 25.3 pg/mL (95% CI [0.94, 49.6], P = .04), whereas sleep deprivation counteracted this decrease. When accounting for the individual trajectories of Aβ42 over time, a difference of 75.8 pg/mL of Aβ42 was shown between the unrestricted sleep and sleep deprivation group (95% CI [3.4, 148.4], P = .04). The individual trajectories of evening and morning Aβ42 concentrations differed between the unrestricted sleep and sleep deprivation groups (P = .04) in contrast to stable Aβ40, tau, and total protein levels. CONCLUSIONS AND RELEVANCE Sleep deprivation, or prolonged wakefulness, interferes with a physiological morning decrease in Aβ42. We hypothesize that chronic sleep deprivation increases cerebral Aβ42 levels, which elevates the risk of Alzheimer disease. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01194713

Benzodiazepine Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis

“…Fastbom et al suggested a mechanism for such a possible 'protective' effect of benzodiazepines on AD, hypothesizing that benzodiazepines (by enhancing the activity of gamma-aminobutyric acid [GABA]) inhibit glutamatergic neurotransmission, and thereby possibly protect against the excitotoxic effects of glutamate, which is believed to be involved in the pathogenesis of AD [11]. Alternatively, and hypothetically, benzodiazepines may indirectly exert a protective effect against the development of AD by improving sleep (through their clinical effects on sleep latency, number of awakenings, and duration and quality of sleep), as sleep deprivation has been shown to increase cerebrospinal fluid levels of Ab42 [27], one of the key proteins involved in the pathogenesis of AD. Such a mechanism would also be in line with our observation that use of benzodiazepines was not associated with an altered risk of VaD.…”

Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Aβ42 Levels in Cognitively Normal Elderly

“…3 This CSF Aβ42 physiological morning decrease is attenuated by total sleep deprivation. 4 All these findings suggest that sleep may play a unique role in AD by resetting soluble Aβ42 to lower levels; however, the precise regulation of this diurnal pattern is not well understood.…”

Neuroendocrine-Metabolic Dysfunction and Sleep Disturbances in Neurodegenerative Disorders: Focus on Alzheimer’s Disease and Melatonin

“…Sleep deprivation for one night [41] or interruption of non-REM sleep [42] in healthy subjects has been shown to increase levels of Aβ 1–42 and Aβ 1–40 in cerebrospinal fluid (CSF). In mice, sleep deprivation caused increases in Aβ peptides in brain interstitial fluid [43], and a direct relationship was established between Aβ and wakefulness.…”